Thu, May 5, 2022
Wed, May 4, 2022
Tue, May 3, 2022
Mon, May 2, 2022
Sun, May 1, 2022
Fri, April 29, 2022

Matthew Harrison Upgraded (VRTX) to Hold and Held Target at $250 on, May 3rd, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. hold-and-held-target-at-250-on-may-3rd-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matthew Harrison of Morgan Stanley, Upgraded "Vertex Pharmaceuticals Incorporated" (VRTX) to Hold and Held Target at $250 on, May 3rd, 2022.

Matthew has made no other calls on VRTX in the last 4 months.



There are 9 other peers that have a rating on VRTX. Out of the 9 peers that are also analyzing VRTX, 3 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Do Kim of "Piper Sandler" Maintained at Hold with Increased Target to $249 on, Friday, April 22nd, 2022
  • Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $274 on, Wednesday, April 6th, 2022
  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $222 on, Thursday, January 27th, 2022


These are the ratings of the 6 analyists that currently disagree with Matthew


  • Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $322 on, Wednesday, April 27th, 2022
  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $300 on, Tuesday, April 5th, 2022
  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $350 on, Monday, April 4th, 2022
  • Brian Skorney of "Baird" Maintained at Buy and Held Target at $240 on, Wednesday, March 23rd, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Thursday, January 27th, 2022
  • Evan Seigerman of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $274 on, Thursday, January 20th, 2022

Publication Contributing Sources